David E. Johnson has been a director since May 2023. Mr. Johnson has served as the Managing Partner of Caligan Partners LP, an SEC-registered investment adviser, since 2017. Mr. Johnson has also served as a member of the board of directors of Liquidia Corporation, a biopharmaceutical company, since 2021, and served as a member of the board of directors of AMAG Pharmaceuticals, Inc., a pharmaceutical company specializing in products treating iron deficiency anemia, from 2019 to 2020. Previously, Mr. Johnson served as Managing Director at the Carlyle Group, a global private equity, alternative asset management and financial services firm, from 2010 to 2017. Before joining Carlyle Group, he served as Vice President in the Principal Investments area at Morgan Stanley, a global financial services and investment management firm, from 2004 to 2010. Prior to joining Morgan Stanley, Mr. Johnson worked at Weiss Asset Management, an investment management firm, from September 2003 to June 2004. In the not-for-profit sector, Mr. Johnson serves as a member of the board of directors of The Children’s Scholarship Fund, Inc., a privately funded tuition assistance program, and previously served on the Executive Committee for the Harvard College Fund. Mr. Johnson holds an A.B. and S.M. in Applied Mathematics from Harvard University.

Robert L. Oliver, Jr. has been a director since May 2023. Mr. Oliver has served as a member of the board of directors of PsyBio Therapeutics Corp., a biotechnology company, since 2021, Neurotez, Inc., a biotechnology company, since 2017, and Hyalo Technologies, LLC, a biotechnology and biopharmaceutical company, since 2017. Mr. Oliver has also served as an Executive Advisor of CELLIX Biosciences, a biopharmaceutical company, since 2018, and Hyalo Technologies, LLC, since 2017. Previously, Mr. Oliver served as a member of the board of directors and as Executive Advisor of Medison Canada from 2018 to 2022 and as a member of the board of directors of Immunomedics, Inc., a biotechnology company, from January 2017 to March 2017. From 2010 to 2020, Mr. Oliver served in a variety of senior positions at Otsuka America Pharmaceutical, Inc., a pharmaceutical company and subsidiary of Otsuka Holdings Co. Ltd., including President and Chief Executive Officer from 2016 to 2017, President and Chief Operating Officer from 2014 to 2016, and Vice President of Sales and Marketing from 2010 to 2014, as well as Chairman of Otsuka Canada Pharmaceutical, Inc. from 2016 to 2020. Before joining Otsuka, Mr. Oliver served in a variety of senior positions at Wyeth Pharmaceuticals, a pharmaceutical company, where he also served as Senior Vice President from 2008 to 2010 and as Vice President from 2005 to 2008. Mr. Oliver began his career with Johnson & Johnson, a pharmaceutical and consumer packaged goods company, where he held a variety of positions from 1989 to 2005. In the not-for-profit sector, Mr. Oliver serves on the Pharma Board of Advisors at Saint Joseph’s University and on the Board of Governors of the Accreditation Council for Medical Affairs. Mr. Oliver holds a B.A. from Rutgers University and an M.B.A. from Saint Joseph’s University.